Aduhelm

Last Updated: December 30, 2022, 07:46 ISTWashington, United StatesThe US Congress report slammed the pharma company Biogen for viewing the Alzheimer’s drug Aduhelm as an unprecedented financial opportunity (Image: Reuters)US Congress…

Biogen said on Tuesday (May 3) that Chief Executive Michel Vounatsos will step down and that the company is pulling back on selling its Alzheimer's drug Aduhelm after the US government's Medicare program restricted coverage of the…

For the past few months, Medicare officials have been inundated with impassioned pleas about how to handle coverage of the controversial new Alzheimer’s drug Aduhelm.Advocacy groups for patients have said the federal insurance program for…

After Biogen’s price cut, advocacy groups for Alzheimer’s patients urged C.M.S. to lower the premium increase. On Monday, the secretary for health and human services, Xavier Becerra, said that he was instructing C.M.S. to re-examine the…

The U.S. Food and Drug Administration's approval of Biogen's Alzheimer's drug Aduhelm in June was heralded as a historic triumph in the fight against a disease that kills thousands of Americans every year.But the excitement around the first…

Biogen slashed the price of its controversial new Alzheimer’s drug Aduhelm on Monday as the drug faces weak sales and mounting criticism.The price was reduced to $28,200 a year from $56,000 on the same day that a group of Alzheimer’s…

The U.S. Food and Drug Administration (FDA) is investigating the death of 75-year-old Canadian woman who participated in clinical trials for the controversial new Alzheimer’s drug Aduhelm.   The unnamed woman died in September 2020 after…

Safety data from those trials was published Monday in the journal JAMA Neurology in a study whose authors included eight Biogen employees.The data showed that 425 of 1,029 patients, or 41 percent, who received the high dose of the drug —…